Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antti S Rannikko

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Nature Cancer|September 2, 2025
Artificial intelligence for prostate cancer diagnosticsAntti S Rannikko
European Urology Focus|July 30, 2017
PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active SurveillanceUtku Lokman, Andrew M Erickson, Hanna Vasarainen, et al.
Scandinavian Journal of Urology|July 20, 2013
Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulationV Matti J Säily, Anssi Pétas, Lotta Joutsi-Korhonen, et al.
The Prostate|July 8, 2020
PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancerAndrew M Erickson, Utku Lokman, Kanerva Lahdensuo, et al.
BJU International|December 15, 2025
Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancerAbderrahim-Oussama Batouche, Eugen Czeizler, Timo-Pekka Lehto, et al.
European Urology|September 23, 2008
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantlyRoderick C N van den Bergh, Stijn Roemeling, Monique J Roobol, et al.
BJU International|January 22, 2009
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 menRoderick C N van den Bergh, Stijn Roemeling, Monique J Roobol, et al.
European Urology Oncology|April 19, 2022
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS StudyHenk Benjamin Luiting, Sebastiaan Remmers, Egbert R Boevé, et al.
BJU International|April 14, 2025
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatmentIvo I de Vos, Cristina Marenghi, Fabio Badenchini, et al.
European Urology Oncology|May 8, 2026
PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three CentersTolou Shadbahr, Juho Pylväläinen, Juho Eineluoto, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Nature Cancer|September 2, 2025
Artificial intelligence for prostate cancer diagnosticsAntti S Rannikko
European Urology Focus|July 30, 2017
PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active SurveillanceUtku Lokman, Andrew M Erickson, Hanna Vasarainen, et al.
Scandinavian Journal of Urology|July 20, 2013
Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulationV Matti J Säily, Anssi Pétas, Lotta Joutsi-Korhonen, et al.
The Prostate|July 8, 2020
PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancerAndrew M Erickson, Utku Lokman, Kanerva Lahdensuo, et al.
BJU International|December 15, 2025
Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancerAbderrahim-Oussama Batouche, Eugen Czeizler, Timo-Pekka Lehto, et al.
European Urology|September 23, 2008
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantlyRoderick C N van den Bergh, Stijn Roemeling, Monique J Roobol, et al.
BJU International|January 22, 2009
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 menRoderick C N van den Bergh, Stijn Roemeling, Monique J Roobol, et al.
European Urology Oncology|April 19, 2022
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS StudyHenk Benjamin Luiting, Sebastiaan Remmers, Egbert R Boevé, et al.
BJU International|April 14, 2025
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatmentIvo I de Vos, Cristina Marenghi, Fabio Badenchini, et al.
European Urology Oncology|May 8, 2026
PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three CentersTolou Shadbahr, Juho Pylväläinen, Juho Eineluoto, et al.
Pageof 2